Rick Admiraal1, Stefan Nierkens2, Moniek A de Witte3, Eefke J Petersen4, Ger-Jan Fleurke4, Luka Verrest2, Svetlana V Belitser5, Robbert G M Bredius6, Reinier A P Raymakers3, Catherijne A J Knibbe7, Monique C Minnema4, Charlotte van Kesteren8, Jurgen Kuball3, Jaap J Boelens9. 1. Paediatric Blood and Marrow Transplant Program, University Medical Centre Utrecht, Utrecht, Netherlands; Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands; Department of Pharmacology, Leiden Academic Centre for Drug Research, University of Leiden, Leiden, Netherlands. 2. Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands. 3. Adult Blood and Marrow Transplant Program, University Medical Centre Utrecht, Utrecht, Netherlands; Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands. 4. Adult Blood and Marrow Transplant Program, University Medical Centre Utrecht, Utrecht, Netherlands. 5. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands. 6. Department of Paediatrics, Leiden University Medical Center, Leiden, Netherlands. 7. Department of Pharmacology, Leiden Academic Centre for Drug Research, University of Leiden, Leiden, Netherlands. 8. Paediatric Blood and Marrow Transplant Program, University Medical Centre Utrecht, Utrecht, Netherlands; Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands. 9. Paediatric Blood and Marrow Transplant Program, University Medical Centre Utrecht, Utrecht, Netherlands; Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands. Electronic address: j.j.boelens@umcutrecht.nl.
Abstract
BACKGROUND: Anti-thymocyte globulin (ATG) is used to prevent graft-versus-host disease (GvHD) after allogeneic haemopoietic cell transplantation (HCT). However, ATG can also cause delayed immune reconstitution of T cells, negatively affecting survival. We studied the relation between exposure to ATG and clinical outcomes in adult patients with acute leukaemia and myelodysplastic syndrome. METHODS: We did a retrospective, pharmacokinetic-pharmacodynamic analysis of data from patients with acute lymphoid leukaemia, acute myeloid leukaemia, or myelodysplastic syndrome receiving their first T-cell repleted allogeneic peripheral blood stem cell HCT with ATG (thymoglobulin) as part of non-myeloablative conditioning from March 1, 2004, to June 1, 2015. Patients received a cumulative intravenous dose of 8 mg/kg divided over 4 days, starting on day -8 before HCT. Active ATG concentrations were measured using a validated bioassay and pharmacokinetic exposure measures (maximum concentration, concentration at time of infusion of the graft, time to reach a concentration of 1 arbitary unit [AU] per day/mL, area under the curve [AUC], and the AUC before and after HCT) were calculated with a validated population pharmacokinetic model. The main outcome of interest was 5-year overall survival, defined as days to death from any cause or last follow-up. Other outcomes were relapse-related mortality, non-relapse mortality, event-free survival, acute and chronic GvHD, and assessment of current and optimum dosing. We used Cox proportional hazard models and Fine-Gray competing risk models for the analyses. FINDINGS: 146 patients were included. ATG exposure after HCT was shown to be the best predictor for 5-year overall survival. Optimum exposure after transplantation was determined to be 60-95 AU per day/mL. Estimated 5-year overall survival in the group who had optimum exposure (69%, 95% CI 55-86) was significantly higher than in the group who had below optimum exposure (32%, 20-51, p=0·00037; hazard ratio [HR] 2·41, 95% CI 1·15-5·06, p=0·020) and above optimum exposure (48%, 37-62, p=0·030; HR 2·11, 95% CI 1·04-4·27, p=0·038). Patients in the optimum exposure group had a greater chance of event-free survival than those in the below optimum exposure group (HR 2·54, 95% CI 1·29-5·00, p=0·007; HR for the above optimum group: 1·83, 0·97-3·47, p=0·063). Above-optimum exposure led to higher relapse-related mortality compared with optimum exposure (HR 2·66, 95% CI 1·12-6·31; p=0·027). Below optimum exposure increased non-relapse mortality compared with optimum exposure (HR 4·36, 95% CI 1·60-11·88; p=0·0040), grade 3-4 acute GvHD (3·09, 1·12-8·53; p=0·029), but not chronic GvHD (2·38, 0·93-6·08; p=0·070). Modelled dosing based on absolute lymphocyte counts led to higher optimum target attainment than did weight-based dosing. INTERPRETATION: Exposure to ATG affects survival after HCT in adults, stressing the importance of optimum ATG dosing. Individualised dosing of ATG, based on lymphocyte counts rather than bodyweight, might improve survival chances after HCT. FUNDING: Netherlands Organization for Health Research and Development and Queen Wilhelma Fund for Cancer Research.
BACKGROUND: Anti-thymocyte globulin (ATG) is used to prevent graft-versus-host disease (GvHD) after allogeneic haemopoietic cell transplantation (HCT). However, ATG can also cause delayed immune reconstitution of T cells, negatively affecting survival. We studied the relation between exposure to ATG and clinical outcomes in adult patients with acute leukaemia and myelodysplastic syndrome. METHODS: We did a retrospective, pharmacokinetic-pharmacodynamic analysis of data from patients with acute lymphoid leukaemia, acute myeloid leukaemia, or myelodysplastic syndrome receiving their first T-cell repleted allogeneic peripheral blood stem cell HCT with ATG (thymoglobulin) as part of non-myeloablative conditioning from March 1, 2004, to June 1, 2015. Patients received a cumulative intravenous dose of 8 mg/kg divided over 4 days, starting on day -8 before HCT. Active ATG concentrations were measured using a validated bioassay and pharmacokinetic exposure measures (maximum concentration, concentration at time of infusion of the graft, time to reach a concentration of 1 arbitary unit [AU] per day/mL, area under the curve [AUC], and the AUC before and after HCT) were calculated with a validated population pharmacokinetic model. The main outcome of interest was 5-year overall survival, defined as days to death from any cause or last follow-up. Other outcomes were relapse-related mortality, non-relapse mortality, event-free survival, acute and chronic GvHD, and assessment of current and optimum dosing. We used Cox proportional hazard models and Fine-Gray competing risk models for the analyses. FINDINGS: 146 patients were included. ATG exposure after HCT was shown to be the best predictor for 5-year overall survival. Optimum exposure after transplantation was determined to be 60-95 AU per day/mL. Estimated 5-year overall survival in the group who had optimum exposure (69%, 95% CI 55-86) was significantly higher than in the group who had below optimum exposure (32%, 20-51, p=0·00037; hazard ratio [HR] 2·41, 95% CI 1·15-5·06, p=0·020) and above optimum exposure (48%, 37-62, p=0·030; HR 2·11, 95% CI 1·04-4·27, p=0·038). Patients in the optimum exposure group had a greater chance of event-free survival than those in the below optimum exposure group (HR 2·54, 95% CI 1·29-5·00, p=0·007; HR for the above optimum group: 1·83, 0·97-3·47, p=0·063). Above-optimum exposure led to higher relapse-related mortality compared with optimum exposure (HR 2·66, 95% CI 1·12-6·31; p=0·027). Below optimum exposure increased non-relapse mortality compared with optimum exposure (HR 4·36, 95% CI 1·60-11·88; p=0·0040), grade 3-4 acute GvHD (3·09, 1·12-8·53; p=0·029), but not chronic GvHD (2·38, 0·93-6·08; p=0·070). Modelled dosing based on absolute lymphocyte counts led to higher optimum target attainment than did weight-based dosing. INTERPRETATION: Exposure to ATG affects survival after HCT in adults, stressing the importance of optimum ATG dosing. Individualised dosing of ATG, based on lymphocyte counts rather than bodyweight, might improve survival chances after HCT. FUNDING: Netherlands Organization for Health Research and Development and Queen Wilhelma Fund for Cancer Research.
Authors: Michael Scordo; Meier Hsu; Ann A Jakubowski; Gunjan L Shah; Christina Cho; Molly A Maloy; Scott T Avecilla; Esperanza B Papadopoulos; Boglarka Gyurkocza; Hugo Castro-Malaspina; Roni Tamari; Richard J O'Reilly; Miguel-Angel Perales; Sergio A Giralt; Brian C Shaffer Journal: Biol Blood Marrow Transplant Date: 2019-01-06 Impact factor: 5.742
Authors: Rosy Dabas; Kareem Jamani; Shahbal B Kangarloo; Poonam Dharmani-Khan; Tyler S Williamson; Samar Ousia; Caylib Durand; Don Morris; Douglas Mahoney; Lynn Savoie; Ahsan Chaudhry; Victor H Jimenez-Zepeda; Faisal M Khan; Andrew Daly; Jan Storek Journal: Blood Adv Date: 2019-05-14
Authors: Claudia Langebrake; Rick Admiraal; Erik van Maarseveen; Agnès Bonnin; Tiene Bauters Journal: Bone Marrow Transplant Date: 2019-05-17 Impact factor: 5.483
Authors: Brigitte Strahm; Felicia Loewecke; Charlotte M Niemeyer; Michael Albert; Marc Ansari; Peter Bader; Yves Bertrand; Birgit Burkhardt; Lydie M Da Costa; Alina Ferster; Alexandra Fischer; Tayfun Güngör; Bernd Gruhn; Ina Hainmann; Friedrich Kapp; Peter Lang; Ingo Müller; Ansgar Schulz; Amina Szvetnik; Marcin Wlodarski; Peter Noellke; Thierry Leblanc; Jean-Hugues Dalle Journal: Blood Adv Date: 2020-04-28
Authors: Moniek A de Witte; Anke Janssen; Klaartje Nijssen; Froso Karaiskaki; Luuk Swanenberg; Anna van Rhenen; Rick Admiraal; Lotte van der Wagen; Monique C Minnema; Eefke Petersen; Reinier A P Raymakers; Kasper Westinga; Trudy Straetemans; Constantijn J M Halkes; Jaap-Jan Boelens; Jürgen Kuball Journal: Blood Adv Date: 2021-01-12
Authors: Michael Scordo; Valkal Bhatt; Patrick Hilden; Melody Smith; Katie Thoren; Christina Cho; Gunjan L Shah; Molly A Maloy; Esperanza B Papadopoulos; Ann A Jakubowski; Scott T Avecilla; Richard J O'Reilly; Hugo Castro-Malaspina; Roni Tamari; Brian C Shaffer; Jaap J Boelens; Miguel-Angel Perales; Sergio A Giralt Journal: Biol Blood Marrow Transplant Date: 2019-03-01 Impact factor: 5.742